300683 海特生物
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-6.836-2.848-5.046-0.6051.371
总资产报酬率 ROA (%)-5.673-2.348-4.256-0.5191.132
投入资产回报率 ROIC (%)-6.372-2.617-4.602-0.5541.211

边际利润分析
销售毛利率 (%)41.81342.84642.70948.46556.922
营业利润率 (%)-39.957-11.666-23.755-0.9913.472
息税前利润/营业总收入 (%)-41.617-13.140-26.421-2.7691.288
净利润/营业总收入 (%)-38.133-11.367-21.293-1.1474.883

收益指标分析
经营活动净收益/利润总额(%)53.046114.20073.68633.17662.355
价值变动净收益/利润总额(%)-11.772-19.703-11.570-303.11568.468
营业外收支净额/利润总额(%)1.9165.5285.86412.800-4.321

偿债能力分析
流动比率 (X)4.5983.5964.2995.0726.349
速动比率 (X)4.2503.2963.9604.6506.062
资产负债率 (%)14.90717.87916.01113.73213.140
带息债务/全部投入资本 (%)0.1321.3755.1826.8086.115
股东权益/带息债务 (%)71,160.9556,750.4641,756.5151,342.0071,498.597
股东权益/负债合计 (%)568.235455.539520.916621.573655.765
利息保障倍数 (X)47.29916.61022.2831.696-0.631

营运能力分析
应收账款周转天数 (天)40.41631.91234.29341.73262.172
存货周转天数 (天)106.888109.866123.94397.30096.042